News and Research

Facebook Cannabidiol (CBD), the major non-psychoactive constituent of Cannabis sativa L., has gained traction as a potential treatment for intractable chronic pain in many conditions. Clinical evidence suggests that CBD provides therapeutic benefit in certain forms of epilepsy and imparts analgesia in certain conditions, and improves quality of life. CBD continues to be Schedule I or […]

Facebook At three years post-Intracept Procedure, statistically significant (p<0.0001) improvements of 31.2 points and 4.3 points were observed compared to baseline, for mean Oswestry Disability Index (ODI) and mean numeric pain score (NPS), respectively. The study also found that 74% fewer patients were actively using opioid medications for low back pain and 84% fewer patients […]

Facebook In one of the first studies to examine this phenomenon, metabolically unhealthy obesity is associated with an increased risk, of around 1.5-fold higher, of any obesity-related cancer, and an even higher risk, of two- to threefold higher, for specific cancers, such as endometrial, liver, and renal cell cancers, compared with metabolically healthy normal weight.  […]

Facebook DUBLIN (Reuters) – Taking Novo Nordisk’s new obesity drug may help reduce the risk of heart disease as well as boosting weight loss, according to new research from the United States. After a year of taking semaglutide, marketed as Wegovy, patients’ risk of suffering from conditions like a heart attack or a stroke over […]

Facebook Researchers from Harvard Medical School found non-ictal cephalic allodynia, established by a quick, inexpensive and noninvasive proprietary test, is an 86% accurate pretreatment predictor of anti-calcitonin gene–related peptide (CGRP) therapy response. To read the rest of the article head over to PainMedicineNews.com More to explorer